Alcohol Use Disorder

Overview and DSM-5 Classification

Alcohol Use Disorder (AUD) is a chronic, relapsing brain disorder characterized by compulsive alcohol use, loss of control over drinking, and a negative emotional state when not drinking. The DSM-5 unified the former categories of alcohol abuse and alcohol dependence into a single dimensional diagnosis, graded as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more of 11 criteria) based on symptom count over the preceding 12 months.

AUD is one of the most prevalent psychiatric conditions in the United States. According to the 2024 National Survey on Drug Use and Health (NSDUH), as reported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), 27.1 million adults aged 18 and older (10.3% of that age group) had AUD in the past year, along with an estimated 775,000 young people aged 12–17 (3.0%). A 2024 report from the Centers for Disease Control and Prevention (CDC) estimates that deaths from excessive alcohol use in the US rose 29.3%, from an average of 137,927 a year in 2016–2017 to 178,307 a year in 2020–2021. Deaths among women rose faster (34.7%) than among men (26.8%).

The disorder sits at the intersection of psychiatry, internal medicine, and public health. Despite effective treatments existing — both pharmacological and psychosocial — fewer than 10% of people with AUD receive any treatment in a given year, reflecting the substantial treatment gap driven by stigma, cost, and limited access.

Back to Table of Contents

Pathophysiology: Acute Effects

Ethanol is a small, lipophilic molecule that crosses the blood-brain barrier rapidly and exerts its intoxicating effects primarily through two receptor systems:

• Gamma-aminobutyric acid-A potentiation: Ethanol acts as a positive allosteric modulator of gamma-aminobutyric acid-A receptors — the brain's principal inhibitory ion channels. By enhancing chloride influx, it produces sedation, anxiolysis, motor incoordination (ataxia), and anterograde amnesia ("blackouts"). The anxiolytic and reinforcing properties are mediated in part through gamma-aminobutyric acid-A receptors in the nucleus accumbens and amygdala.
• N-methyl-D-aspartate (NMDA) receptor antagonism: Ethanol inhibits N-methyl-D-aspartate (NMDA) glutamate receptors, the brain's primary excitatory channels involved in learning and memory consolidation. This contributes to the amnestic effects of acute intoxication and, with chronic exposure, becomes central to tolerance and withdrawal physiology.

Additionally, ethanol increases dopamine release in the mesolimbic reward pathway (ventral tegmental area to nucleus accumbens), reinforcing repeated use. It also interacts with opioid receptors — endogenous opioid release triggered by alcohol contributes to the pleasurable, euphoric component of drinking, a mechanism directly targeted by naltrexone.

At high blood alcohol concentrations (>0.25 g/dL), brainstem depression can produce respiratory suppression, aspiration risk, and death — the mechanism of acute alcohol poisoning.

Back to Table of Contents

Neuroadaptation and Tolerance

With chronic heavy alcohol exposure, the brain compensates for persistent gamma-aminobutyric acid-A potentiation and N-methyl-D-aspartate inhibition through homeostatic neuroadaptation:

• Gamma-aminobutyric acid-A downregulation: Chronic alcohol leads to reduced expression, altered subunit composition, and internalization of gamma-aminobutyric acid-A receptors, making them less sensitive to both ethanol and endogenous gamma-aminobutyric acid (GABA). This underlies the tolerance requiring ever-larger amounts to achieve the same effect.
• N-methyl-D-aspartate upregulation: In parallel, N-methyl-D-aspartate receptors are upregulated — more receptors are expressed at higher sensitivity. This compensatory excitatory surge is quiescent as long as alcohol is present to suppress it, but becomes dangerously unmasked upon cessation.

Neuroimaging and post-mortem studies also document reduced gray matter volume in the prefrontal cortex (PFC), impairing executive function, impulse control, and decision-making — the very faculties needed to regulate drinking. These PFC changes correlate with relapse risk and improve partially (but not completely) with sustained abstinence. The dopamine reward system is also dysregulated: baseline dopamine tone falls, making ordinary pleasures less rewarding ("anhedonia") and making alcohol the primary reliable pleasure trigger — a hallmark of addiction.

Neuroadaptation explains why stopping suddenly is dangerous, why cravings persist long into sobriety (opponent-process model), and why early relapse rates are high even among genuinely motivated individuals.

Back to Table of Contents

Alcohol Withdrawal Syndrome

When a neuroadapted brain is abruptly deprived of alcohol, the compensatory upregulation of excitatory (N-methyl-D-aspartate) systems and downregulation of inhibitory (gamma-aminobutyric acid-A) systems creates central nervous system (CNS) hyperexcitability — the physiological basis of the alcohol withdrawal syndrome (AWS). AWS is not simply uncomfortable; it can be life-threatening.

Timeline of withdrawal symptoms:

• 6–24 hours: Tremor (intention tremor of hands), tachycardia, hypertension, diaphoresis, nausea and vomiting, anxiety, and insomnia. Some patients experience withdrawal seizures as early as 6 hours.
• 6–48 hours: Peak risk for withdrawal seizures — typically generalized tonic-clonic, often solitary but can cluster. History of prior seizures or delirium tremens sharply increases risk.
• 12–48 hours: Alcoholic hallucinosis — vivid auditory (less often visual) hallucinations with intact orientation, distinct from delirium tremens.
• 48–96 hours: Delirium tremens (DTs) — the most severe manifestation. Characterized by global confusion and disorientation, agitation, autonomic storm (fever, tachycardia, hypertension, diaphoresis), and visual hallucinations (classically insects or small animals), sometimes with formication — a tactile hallucination, the feeling of insects crawling on or under the skin. Untreated mortality is estimated at 5–15%; with appropriate intensive care unit-level management it falls below 1%.

The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) is the validated 10-item scale used to quantify withdrawal severity and guide symptom-triggered benzodiazepine dosing. Common protocols start medication at scores of 10 or more; scores of 15–20 or more indicate severe withdrawal that needs close monitoring.

Back to Table of Contents

Medical Complications

Chronic heavy alcohol use injures virtually every organ system. The most clinically significant complications include:

Liver: The liver metabolizes ~90% of ingested ethanol. The progression of alcoholic liver disease follows a well-defined spectrum:

• Alcoholic fatty liver (steatosis): Reversible with abstinence; present in up to 90% of heavy drinkers.
• Alcoholic hepatitis: Inflammatory injury with jaundice, right upper quadrant pain, fever; severe cases carry 28-day mortality of 30–50%.
• Cirrhosis: Irreversible fibrosis with portal hypertension, varices, ascites, and hepatic encephalopathy. Present in ~10–20% of heavy drinkers over decades.
• Hepatocellular carcinoma (HCC): Arises on the background of cirrhosis; alcohol is a leading etiology globally.

Brain — Wernicke-Korsakoff Syndrome: Thiamine (vitamin B1) deficiency — almost universal in severe AUD due to poor diet, impaired gut absorption, and reduced hepatic storage — precipitates:

• Wernicke encephalopathy: The classic triad of confusion, ataxia (broad-based gait), and ophthalmoplegia (conjugate gaze palsy, nystagmus). Only ~16% of cases present with all three features; in practice any single feature is treated with urgent intravenous (IV) thiamine. Administration of glucose before thiamine can precipitate or worsen Wernicke encephalopathy by consuming residual thiamine.
• Korsakoff syndrome: The chronic amnestic sequel — profound anterograde amnesia (inability to form new memories) with relative preservation of remote memory, and characteristic confabulation (unconscious fabrication of plausible but false memories to fill gaps). Only ~25% recover substantially.

Peripheral neuropathy: Length-dependent axonal neuropathy (distal stocking-glove sensory loss, burning pain, weakness) affects ~25–50% of patients with AUD and is caused by both direct ethanol toxicity and B-vitamin deficiencies.

Cardiovascular: Alcoholic cardiomyopathy (dilated cardiomyopathy from direct myocardial toxicity), atrial fibrillation ("holiday heart"), and hypertension are all common. Light-to-moderate drinking may have modest cardioprotective effects in some populations, but heavy drinking is clearly cardiotoxic and the J-curve relationship is contested in recent Mendelian randomization studies.

Pancreatitis: Both acute and chronic pancreatitis are strongly associated with heavy drinking; alcohol accounts for 30–35% of acute pancreatitis cases and up to 70–80% of chronic pancreatitis.

Cancer: The International Agency for Research on Cancer (IARC) classifies ethanol as a Group 1 carcinogen. Alcohol causally increases risk for at least seven cancers: oral cavity, pharynx, larynx, esophagus, liver, colorectum, and female breast. There is no established safe threshold.

Fetal Alcohol Spectrum Disorder (FASD): Prenatal alcohol exposure is the leading preventable cause of intellectual disability and congenital birth defects. Fetal alcohol syndrome (FAS) — the full syndrome — includes growth restriction, characteristic facial features, and central nervous system abnormalities. FASD represents the full spectrum of less severe but still significant neurodevelopmental effects.

Back to Table of Contents

Diagnosis and Screening

AUD is a clinical diagnosis based on DSM-5 criteria. The patient must meet at least 2 of the following 11 criteria in a 12-month period:

1. Drinking more or longer than intended.
2. Repeated unsuccessful attempts to cut down or stop.
3. Spending a great deal of time obtaining, using, or recovering from alcohol.
4. Strong craving or urge to drink.
5. Failure to fulfill major role obligations at work, school, or home.
6. Continued use despite persistent social or interpersonal problems caused by alcohol.
7. Giving up important activities because of alcohol.
8. Repeated use in physically hazardous situations.
9. Continued use despite knowing a physical or psychological problem is caused or worsened by alcohol.
10. Tolerance (needing more for the same effect).
11. Withdrawal symptoms when stopping or cutting down.

Validated screening tools:

• AUDIT-C (3-item Alcohol Use Disorders Identification Test — Consumption): Score ≥3 in women, ≥4 in men indicates hazardous drinking and warrants full AUDIT follow-up.
• CAGE questionnaire: Four yes/no questions (Cut down? Annoyed by criticism? Guilty? Eye-opener?) Two or more positives suggest AUD.
• AUDIT (full 10-item): Score 8–15 indicates hazardous use; 16–19 harmful use; ≥20 likely dependence.

Laboratory biomarkers:

• Aspartate aminotransferase (AST):alanine aminotransferase (ALT) ratio >2:1 in a patient with liver disease strongly suggests alcoholic hepatitis (mitochondrial aspartate aminotransferase release predominates).
• gamma-glutamyl transferase (GGT): Sensitive but non-specific marker of chronic heavy use; returns to normal within 4–8 weeks of abstinence.
• MCV (mean corpuscular volume): Macrocytosis (MCV >100 fL) from folate/B12 deficiency and direct marrow toxicity.
• Carbohydrate-deficient transferrin (CDT): More specific objective biomarker for chronic heavy drinking (>50–80 g/day for >1 week); useful for monitoring abstinence.
• Phosphatidylethanol (PEth): Blood biomarker with 3–4 week detection window; increasingly used in transplant and custody settings.

Back to Table of Contents

Medical Detoxification

Medical detoxification manages the acute withdrawal syndrome safely; it is not itself a treatment for AUD but a necessary first step enabling subsequent treatment. Setting (inpatient vs. outpatient) is determined by withdrawal severity, history of seizures or DTs, comorbid medical conditions, and social supports.

Benzodiazepines are first-line for AWS, acting as gamma-aminobutyric acid-A positive allosteric modulators — they "replace" ethanol's inhibitory effect while allowing gradual dose taper:

• Diazepam (long half-life, active metabolites) preferred for severe withdrawal — provides built-in taper through accumulation; risk of accumulation in hepatic failure.
• Lorazepam (intermediate half-life, no active metabolites) preferred in elderly, liver disease, or respiratory compromise.
• Oxazepam is an alternative in liver impairment (no active metabolites, phase II metabolism only). Chlordiazepoxide does not share that profile: it is broken down into a series of active products (desmethylchlordiazepoxide, demoxepam, desmethyldiazepam, and oxazepam), and a 1978 study found its clearance fell in cirrhosis (7.7 versus 15.3 mL per minute in matched controls), which may account in part for the oversedation seen in people with liver disease.
• Symptom-triggered dosing (guided by CIWA-Ar scores) uses less total benzodiazepine and shortens treatment duration vs. fixed-schedule regimens, without sacrificing safety.

Phenobarbital serves as an adjunct or alternative for benzodiazepine-refractory withdrawal, acting on both gamma-aminobutyric acid-A and N-methyl-D-aspartate systems. Evidence for phenobarbital-alone protocols in the emergency department (ED) is growing.

Standard teaching is to give intravenous thiamine (100–500 mg) before any glucose-containing fluids in patients with suspected AUD, to prevent precipitation or worsening of Wernicke encephalopathy. A 2012 review of 19 papers found no evidence on this order above the level of case reports: it concluded that delaying glucose for people with low blood sugar cannot be recommended, while prompt thiamine after or alongside the return to normal blood sugar is recommended, and noted case reports in which prolonged glucose without thiamine was a risk factor for Wernicke encephalopathy. Thiamine stores may be depleted to days in severely malnourished patients; intravenous route ensures absorption regardless of gut dysfunction.

Magnesium is often given because deficiency is frequent in AUD. A 2013 Cochrane review (4 trials, 317 people) found insufficient evidence to determine whether magnesium is beneficial or harmful for the treatment or prevention of alcohol withdrawal syndrome. Multivitamin supplementation addresses broad B-vitamin deficiency.

Back to Table of Contents

Pharmacotherapy for Alcohol Use Disorder

Three U.S. Food and Drug Administration-approved medications reduce drinking or support abstinence. All are under-prescribed — fewer than 5% of patients with AUD receive pharmacotherapy.

Naltrexone is a competitive μ-opioid receptor antagonist. By blocking opioid receptors, it prevents the endorphin-mediated pleasurable reward of drinking, reducing the urge to continue once started ("cue-induced craving blunting"). Available as:

• Oral naltrexone 50 mg/day: a 2014 meta-analysis of trials lasting at least 12 weeks (Jonas et al.) found that 12 people needed to be treated (number needed to treat, NNT, 12) to prevent one return to heavy drinking. Low adherence limits real-world effectiveness.
• Extended-release injectable naltrexone (380 mg by intramuscular (IM) injection monthly): Eliminates adherence as a barrier; pivotal randomized controlled trial (RCT) showed significant reduction in heavy drinking days vs. placebo. Cost (~$1,500/injection) is a barrier.
• Contraindicated in patients taking opioid medications or with acute hepatitis or liver failure; liver function tests (LFTs) are used to monitor for liver injury.

Acamprosate (calcium acetylhomotaurinate) modulates N-methyl-D-aspartate and gamma-aminobutyric acid receptor systems, reducing the glutamate-driven hyperexcitability and anxiety that characterize protracted abstinence. Evidence is strongest for supporting abstinence in already-detoxified patients.

• Dosing: 666 mg (two 333 mg tablets) three times daily — the three-times-daily regimen is a significant compliance burden.
• Renally cleared — the dose is reduced, or the drug not used, in significant renal impairment. No hepatic metabolism — safe in liver disease.
• The COMBINE trial found no significant superiority over placebo for acamprosate, in contrast to positive European trials; meta-analyses suggest modest but real benefits for abstinence.
• The 2014 Jonas meta-analysis (122 randomized trials and 1 cohort study, 22,803 people) found an NNT of 12 for acamprosate to prevent a return to any drinking, and no significant difference between acamprosate and oral naltrexone when the two were compared directly. Among medicines used off-label, it found moderate evidence for nalmefene and topiramate on some drinking measures.

Disulfiram inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion. The resulting flushing, nausea, vomiting, tachycardia, and hypotension (disulfiram-ethanol reaction) deter drinking through aversive conditioning.

• Effectiveness depends entirely on patient motivation and monitored administration. A 2014 meta-analysis of 22 randomized controlled trials (RCTs) found disulfiram more successful than control treatments overall, but only the open-label trials, where participants knew they were taking it, showed a significant benefit; trials with blind designs showed no effect. The authors explain why: disulfiram works through the threat of the reaction, and in a blinded trial that threat is spread evenly across every group, including the controls. Supervised or directly observed therapy dramatically improves outcomes.
• Multiple drug interactions (metronidazole, isoniazid); contraindicated in coronary artery disease; rare hepatotoxicity.

Gabapentin (off-label): Increasingly used for both alcohol withdrawal and relapse prevention. A 2014 JAMA Internal Medicine randomized controlled trial showed gabapentin 1800 mg/day significantly reduced heavy drinking and improved sleep and mood vs. placebo. Its gamma-aminobutyric acid-mimetic and anti-craving properties, combined with safety in liver disease and favorable side-effect profile, make it an attractive option.

Topiramate (off-label): gamma-aminobutyric acid facilitation and glutamate antagonism; multiple randomized controlled trials show reduction in heavy drinking days and drinks per day. Cognitive side effects (word-finding difficulty) and metabolic acidosis limit tolerability.

Semaglutide (experimental for AUD): In a 2025 phase 2 randomized trial of 48 adults with AUD who were not seeking treatment, low weekly doses of semaglutide, a glucagon-like peptide-1 (GLP-1) medicine, given for 9 weeks reduced the amount of alcohol drunk in a laboratory drinking test, drinks per drinking day, and weekly craving. It did not change average drinks per day or the number of drinking days. The authors describe the results as initial evidence that justifies larger trials.

Back to Table of Contents

Behavioral Treatments

Pharmacotherapy alone is insufficient; behavioral and psychosocial treatments address the cognitive, emotional, and social dimensions of AUD. These are most effective when combined with medication.

• Alcoholics Anonymous (AA) and 12-Step Facilitation (TSF): AA is the most widely available and utilized recovery support in the US. The 12-step model emphasizes peer support, surrender of control, and spiritual growth. TSF is a manualized therapy designed to increase AA attendance. A 2020 Cochrane review (Kelly JF et al.; 27 studies, 10,565 participants) found that manualized AA/TSF produced higher rates of continuous abstinence at 12 months than other clinical treatments such as cognitive behavioral therapy (CBT) or motivational enhancement therapy (MET) (risk ratio 1.21; 2 studies, 1,936 participants; high-certainty evidence), and the effect held at 24 and 36 months, likely through peer accountability and community support.
• Cognitive Behavioral Therapy (CBT): Identifies and modifies maladaptive thoughts and behaviors related to drinking; teaches coping skills to manage triggers, cravings, and high-risk situations. Strong evidence base; durable effects through skill acquisition even after treatment ends.
• Motivational Enhancement Therapy (MET) / Motivational Interviewing (MI): A directive, patient-centered approach that resolves ambivalence about behavior change by eliciting the patient's own motivations. Particularly effective as a brief intervention (2–4 sessions) in primary care settings. The FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) guides brief intervention delivery.
• Contingency Management (CM): Provides tangible rewards (vouchers, prizes) for verified abstinence via urine testing. Strong evidence in substance use disorders broadly; less studied specifically in AUD but promising.
• Couples and Family Therapy: Addresses relational dynamics that maintain drinking and builds family support for recovery. Community Reinforcement Approach and Family Training (CRAFT) has strong evidence for engaging resistant patients in treatment.

Residential treatment, partial hospitalization, and intensive outpatient programs (IOP) provide structured environments for severe AUD or those without a stable, sober home environment. The American Society of Addiction Medicine (ASAM) criteria guide level-of-care placement decisions.

Back to Table of Contents

Key Research Papers

1. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III." JAMA Psychiatry. 2015;72(8):757-66. — PubMed PMID: 26039070
2. Saitz R. "Clinical practice. Unhealthy alcohol use." N Engl J Med. 2005;352(6):596-607. — PubMed PMID: 15703424
3. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. "Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)." Br J Addict. 1989;84(11):1353-7. — PubMed PMID: 2597811
4. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. "Pharmacological treatment of alcohol dependence: a review of the evidence." JAMA. 1999;281(14):1318-25. — PubMed PMID: 10208148
5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. "Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial." JAMA. 2006;295(17):2003-17. — PubMed PMID: 16670409
6. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. "A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence." Arch Gen Psychiatry. 1999;56(8):719-24. — PubMed PMID: 10435606
7. Kranzler HR, Jaffe JH. "Alcohol-related disorders." Kaplan & Sadock's Comprehensive Textbook of Psychiatry. (Textbook chapter; not indexed in PubMed.)
8. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. "Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders." Lancet. 2009;373(9682):2223-33. — PubMed PMID: 19560604
9. Lieber CS. "Hepatic and other medical disorders of alcoholism: from pathogenesis to treatment." J Stud Alcohol. 1998;59(1):9-25. — PubMed PMID: 9498311
10. Cargiulo T. "Understanding the health impact of alcohol dependence." Am J Health Syst Pharm. 2007;64(5 Suppl 3):S5-11. — PubMed PMID: 17322182
11. Thomson AD, Cook CC, Touquet R, Henry JA. "The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department." Alcohol Alcohol. 2002;37(6):513-21. — PubMed PMID: 12414541
12. Esser MB, Sherk A, Liu Y, Naimi TS. "Deaths from Excessive Alcohol Use - United States, 2016-2021." MMWR Morb Mortal Wkly Rep. 2024;73(8):154-161. — PubMed PMID: 38421934
13. Skinner MD, Lahmek P, Pham H, Aubin HJ. "Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis." PLoS One. 2014;9(2):e87366. — PubMed PMID: 24520330
14. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. "Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis." JAMA. 2014;311(18):1889-900. — PubMed PMID: 24825644
15. Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. "Clinical pharmacokinetics of chlordiazepoxide." Clin Pharmacokinet. 1978;3(5):381-94. — PubMed PMID: 359214
16. Roberts RK, Wilkinson GR, Branch RA, Schenker S. "Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium)." Gastroenterology. 1978;75(3):479-85. — PubMed PMID: 680505
17. Sarai M, Tejani AM, Chan AH, Kuo IF, Li J. "Magnesium for alcohol withdrawal." Cochrane Database Syst Rev. 2013;(6):CD008358. — PubMed PMID: 23740536
18. Schabelman E, Kuo D. "Glucose before thiamine for Wernicke encephalopathy: a literature review." J Emerg Med. 2012;42(4):488-94. — PubMed PMID: 22104258
19. Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial." JAMA Psychiatry. 2025;82(4):395-405. — PubMed PMID: 39937469
20. Kelly JF, Humphreys K, Ferri M. "Alcoholics Anonymous and other 12-step programs for alcohol use disorder." Cochrane Database Syst Rev. 2020;3(3):CD012880. — PubMed PMID: 32159228
21. National Institute on Alcohol Abuse and Alcoholism. "Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics" (2024 NSDUH figures; updated August 2025). — niaaa.nih.gov

Back to Table of Contents

Connections

• Psychiatry
• What Alcohol Does Inside Your Liver — interactive animation
• Addiction
• Depression
• Anxiety
• Post-Traumatic Stress Disorder
• Gambling Disorder
• Gastroenterology Diseases
• Thiamine (Vitamin B1)
• Magnesium

Featured Videos